Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.42 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | DHODH | Q02127 | 2/20 | 0.35 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7010290 | 0.90 | MAPT (0.41) | MEN1KMT2ANPSR1MAPTLMNA | |
| SCHEMBL12889528 | 0.88 | MEN1 (0.44) | MEN1KMT2ANPSR1MAPTLMNA | |
| SCHEMBL2924716 | 0.88 | MAPT (0.40) | MEN1KMT2ANPSR1MAPTLMNA | |
| SCHEMBL5525147 | 0.88 | NPSR1 (0.40) | MEN1KMT2ANPSR1MAPTLMNA | |
| SCHEMBL9095929 | 0.87 | MAPT (0.39) | MEN1KMT2ANPSR1MAPTLMNA | |
| SCHEMBL10773784 | 0.86 | NPSR1 (0.40) | MEN1KMT2ANPSR1MAPTLMNA | |
| SCHEMBL8434387 | 0.86 | NPSR1 (0.40) | MEN1KMT2ANPSR1MAPTLMNA | |
| SCHEMBL10544905 | 0.86 | NPSR1 (0.42) | MEN1KMT2ANPSR1MAPTLMNA | |
| SCHEMBL8160156 | 0.86 | CES2 (0.50) | MEN1KMT2ANPSR1MAPTLMNA | |
| SCHEMBL10544901 | 0.86 | NPSR1 (0.42) | MEN1KMT2ANPSR1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-5213836-A | — | — | None | — | — | JP | disclosed |
| CN-117903163-A | Fluoroquinolone compound with spiro structure at C7 position and application thereof | 广东工业大学 | 2024-04-19 | — | — | CN | disclosed |
| EP-1401829-B1 | NOVEL HETEROCYCLIC ANTIBACTERIAL COMPOUNDS | MICROBIOTIX INC (US) | 2012-08-22 | — | — | EP | disclosed |
| US-6777420-B2 | A URACIL COMPOUNDS AS ENZYME INHIBITORS, INHIBIT BACTERIAL DNA POLYMERASE, TREATING BACTERIAL DISEASES | MICROBIOTIX, INC. | 2004-08-17 | — | — | US | disclosed |
| US-20030181719-A1 | Novel heterocyclic antibacterial compounds | MICROBIOTIX, INC. | 2003-09-25 | — | — | US | disclosed |
| EP-0952151-B1 | Intermediates for use in preparing novel pyridonecarboxylic acid derivatives or their salts | WAKUNAGA PHARMA CO LTD (JP) | 2003-05-28 | — | — | EP | disclosed |
| EP-0992501-B1 | Pyridonecarboxylic acid derivatives as antibacterial agents | WAKUNAGA PHARMA CO LTD (JP) | 2002-08-28 | — | — | EP | disclosed |
| EP-0911327-B1 | NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVES OR THEIR SALTS AND ANTIBACTERIAL AGENT COMPRISING THE SAME AS THE ACTIVE INGREDIENT | WAKUNAGA PHARMA CO LTD (JP) | 2001-12-05 | — | — | EP | disclosed |
| US-6156903-A | Pyridonecarboxylic acid derivatives or their salts, and antibacterial agents containing the same as their effective components | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2000-12-05 | — | — | US | disclosed |
| US-6133284-A | EXCELLENT BACTERICIDAL PROPERTIES AND ORAL ABSORPTION; INFECTIONS FROM GRAMNEGATIVE AND -POSITIVE BACTERIA; INTESTINAL ABSORPTION, METABOLIC STABILITY; SIDE EFFECT REDUCTION; NONPHOTOTOXICITY AND NONCYTOTOXICITY | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2000-10-17 | — | — | US | disclosed |
| US-4762831-A | PROMOTE ANIMAL GROWTH | BAYER AKTIENGESELLSCHAFT (DE) | 1988-08-09 | — | — | US | disclosed |
| US-4755513-A | Antimicrobial 1-substituted phenyl-4-oxoquinoline-3-carboxylic acid compounds | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1988-07-05 | — | — | US | disclosed |
| US-4753925-A | Antibacterial 1,7-diamino-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids | BAYER AKTIENGESELLSCHAFT (DE) | 1988-06-28 | — | — | US | disclosed |
| US-4705788-A | Novel antibacterial 7-amino-1(substituted cyclopropyl)-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids | BAYER AKTIENGESELLSCHAFT (DE) | 1987-11-10 | — | — | US | disclosed |
| US-4684648-A | Antimicrobial 1-substituted phenyl-4-oxoquinoline-3-carboxylic acid compounds and compositions thereof | OTSUKA PHARMACEUTICAL COMPANY LIMITED (JP) | 1987-08-04 | — | — | US | disclosed |
| EP-0191185-A1 | Quinoline-carboxylic acid derivatives | DAIICHI SEIYAKU CO., LTD. (JP) | 1986-08-20 | — | — | EP | disclosed |
| US-4599334-A | 7-(3-aryl-1-piperazinyl)- and 7-(3-cyclohexyl-1-piperazinyl)-3-quinolonecarboxylic acid antibacterials | BAYER AKTIENGESELLSCHAFT (DE) | 1986-07-08 | — | — | US | disclosed |
| EP-0181521-A1 | Antimicrobial 1-substituted Phenyl-4-oxoquinoline-3-carboxylic acid compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-21 | — | — | EP | disclosed |
| US-4588726-A | 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(3-oxo-1-piperazinyl)-3-quinolinecarboxylic acid antibacterial agents | BAYER AKTIENGESELLSCHAFT (DE) | 1986-05-13 | — | — | US | disclosed |
| US-4556658-A | 7-Amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-quinoline-3-carboxylic acids and antibacterial agents containing these compounds | BAYER AKTIENGESELLSCHAFT (DE) | 1985-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181719-A1 | Novel heterocyclic antibacterial compounds | TOP1, TOP2A, TOP2B | MEN1 4240/4885KMT2A 2259/4885NPSR1 4813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.